Georgia Medicare Prescription Payment Plan: M3P Smoothing Guide

::: hero

By Brevy Care Team · Last verified May 13, 2026

The Medicare Prescription Payment Plan, abbreviated M3P and commonly called "smoothing," is one of the most innovative consumer protections in the Inflation Reduction Act of 2022. Established by Section 11202 of the IRA (Public Law 117-169) and codified at Section 1860D-2(b)(2)(E) of the Social Security Act, M3P allows Medicare Part D beneficiaries to spread their out-of-pocket prescription drug costs across the plan year in monthly installments rather than paying high upfront costs at the pharmacy counter. M3P took effect January 1, 2025, after a phased implementation announced in CMS guidance at 89 Fed. Reg. 71684 (September 6, 2024). The mechanism works as follows: when a Part D beneficiary fills a prescription, instead of paying the cost-sharing at the pharmacy counter, they can opt into M3P. The Part D plan pays the pharmacy directly. The plan then bills the beneficiary in monthly installments calculated based on the beneficiary's accumulated cost-sharing and remaining months in the plan year. The result is dramatic for beneficiaries facing high upfront costs. A beneficiary facing a $1,200 prescription cost-share in January no longer pays $1,200 at the counter. Instead, they pay roughly $100 per month over the remaining 12 months of the plan year. The mechanism is particularly valuable for beneficiaries with high upfront prescription costs (specialty drugs, monthly fills above $500), beneficiaries on multiple drugs whose combined monthly out-of-pocket exceeds their cash flow, beneficiaries with chronic conditions whose annual out-of-pocket would otherwise hit the $2,000 cap (IRA Section 11201) in a single month, low-income beneficiaries not on the Part D Low-Income Subsidy who would otherwise face acute affordability barriers, and beneficiaries managing cancer, multiple sclerosis, rheumatoid arthritis, or other conditions requiring high-cost biologics. The first year of M3P (2025) showed strong uptake among Medicare beneficiaries nationwide. For 2026, M3P is fully integrated with the $2,000 OOP cap and the Drug Price Negotiation Program. This guide explains the federal framework, the operational mechanics, the opt-in and opt-out process, the interaction with the $2,000 OOP cap, the interaction with negotiated drugs and insulin and vaccines and LIS, the practical considerations for choosing whether to use M3P, and worked examples for typical Georgia beneficiaries. :::

::: callout Key takeaways for Georgia Medicare Prescription Payment Plan

• The Medicare Prescription Payment Plan (M3P), or "smoothing," is established by Section 11202 of the IRA 2022 (Public Law 117-169) and codified at Section 1860D-2(b)(2)(E) of the Social Security Act.
• M3P took effect January 1, 2025, with CMS implementation rules at 42 CFR 423.137 and 89 Fed. Reg. 71684 (September 2024).
• M3P allows Part D beneficiaries to spread out-of-pocket prescription costs across the plan year in monthly installments rather than paying high upfront costs at the pharmacy counter.
• M3P is voluntary; beneficiaries must affirmatively opt in.
• All Part D plans (PDP and MA-PD) must offer M3P.
• M3P does not reduce total cost; it spreads cost over time. The total annual obligation is capped at $2,100 in 2026 under Section 11201 IRA 2022 (up from $2,000 in 2025).
• M3P is most valuable for beneficiaries with high upfront prescription costs, multiple drugs, or limited liquidity for large counter payments.
• M3P interacts with: $2,000 OOP cap (cap caps the total); Drug Price Negotiation Program (M3P available on negotiated drugs); insulin $35 cap (M3P available on insulin); LIS (typically unnecessary for LIS recipients); ACIP-recommended vaccines (vaccines are $0, M3P irrelevant).
• GeorgiaCares (SHIP) at 1-866-552-4464 provides free unbiased counseling on whether M3P is right for you. :::

What is the Medicare Prescription Payment Plan

The Medicare Prescription Payment Plan, abbreviated M3P, is a payment option for Medicare Part D beneficiaries that allows them to spread their out-of-pocket prescription drug costs across the plan year in monthly installments. The plan was established by Section 11202 of the Inflation Reduction Act of 2022 (Public Law 117-169), signed into law August 16, 2022. Section 11202 amended Section 1860D-2(b)(2) of the Social Security Act to add subsection (E), which establishes the M3P framework.

The basic concept of M3P is straightforward but the implementation involved substantial CMS rulemaking. Under traditional Part D cost-sharing, a beneficiary pays the deductible (up to the standard deductible, though many plans use lower deductibles), then pays cost-sharing on each prescription at the pharmacy counter (a copay or coinsurance percentage), up to the catastrophic threshold. Under the out-of-pocket cap established by Section 11201 IRA 2022 ($2,000 in 2025; $2,100 in 2026), the beneficiary's annual cost-sharing is capped at this amount.

The traditional cost-sharing model creates a cash flow challenge for some beneficiaries. A beneficiary prescribed a high-cost specialty drug (say, a $5,000 retail biologic) might owe $1,500 to $2,000 in cost-sharing for that single prescription. Paying $2,000 at the pharmacy counter in a single month is impossible for many seniors living on fixed incomes. Even though the annual cap limits total cost, the timing of payments creates acute affordability problems.

M3P solves the timing problem. Instead of paying the cost-sharing at the counter, the beneficiary opts into M3P. The Part D plan pays the cost-sharing to the pharmacy on behalf of the beneficiary. The pharmacy releases the prescription. The plan then bills the beneficiary in monthly installments calculated based on the accumulated cost-sharing divided by the remaining months in the plan year. The beneficiary pays the plan directly each month.

The mechanism does not reduce total cost. The beneficiary still owes the full cost-sharing eventually. But the timing changes from "all at once at the counter" to "monthly over the plan year." For beneficiaries with limited monthly cash flow but predictable monthly income, the difference is profound.

The legal authority for M3P

The legal authority for M3P sits in three layers. The statutory authority is Section 11202 IRA 2022 (Public Law 117-169) and Section 1860D-2(b)(2)(E) of the Social Security Act. The regulatory authority is 42 CFR 423.137 (new under the 2024 CMS final rule) and 42 CFR 423.138. The sub-regulatory guidance is CMS implementation memoranda and Federal Register notices including 89 Fed. Reg. 71684 (September 6, 2024) and 88 Fed. Reg. 78884 (November 17, 2023).

The CMS rulemaking developed the operational details of M3P. Some of the key operational requirements established by the rules:

• All Part D plans (standalone PDPs and Medicare Advantage prescription drug plans, MA-PDs) must offer M3P
• Beneficiaries must opt in voluntarily; auto-opt-in is not required
• Plans must process opt-in requests within 24 hours
• Plans must provide accurate monthly billing
• Plans may not impose interest or fees beyond the cost-sharing itself
• Beneficiaries may opt out at any time
• Continued coverage is required even if M3P payments are missed (medication adherence protection)

The rules also addressed beneficiary protections during opt-in and opt-out, billing dispute procedures, plan-to-plan portability of M3P balances, and consumer education requirements.

How M3P works step by step

The M3P mechanism operates through a series of steps that occur when a beneficiary fills a prescription:

Step 1: Beneficiary fills prescription at pharmacy.

Step 2: Pharmacy processes the prescription through the Part D plan's electronic claims system. The system calculates the beneficiary's cost-sharing based on standard Part D rules (deductible status, formulary tier, accumulated TrOOP).

Step 3: The plan's system checks whether the beneficiary is opted into M3P.

Step 4a (if opted into M3P): The plan pays the cost-sharing directly to the pharmacy. The pharmacy releases the prescription. The beneficiary pays $0 at the counter. The plan adds the cost-sharing to the beneficiary's M3P balance.

Step 4b (if not opted into M3P): The beneficiary pays the cost-sharing at the counter as usual.

Step 5: At the end of each month, the plan calculates the M3P monthly bill for opted-in beneficiaries. The formula: (Total accumulated cost-sharing to date) divided by (Remaining months in plan year).

Step 6: The beneficiary receives a monthly bill from the plan. The bill shows the amount due, the payment due date, and the accumulated balance.

Step 7: The beneficiary pays the plan directly (online, by mail, by phone). The bill may be paid in full or in installments (subject to plan terms).

Step 8: As new fills occur during the month, the cost-sharing for those fills is added to the M3P balance. The next month's bill reflects the updated balance and the remaining months.

The monthly bill recalculates each month. A beneficiary who hits the OOP cap mid-year owes the accumulated amount over the remaining months. New fills after the cap are $0 (Part D pays everything) and do not add to the M3P balance.

Monthly billing calculation in detail

The monthly billing calculation is the heart of M3P. The basic formula is:

Monthly Bill = Accumulated Cost-Sharing / Months Remaining in Plan Year

Let's work through an example. Suppose a beneficiary opts into M3P in January and fills a $1,200 prescription in January.

• January cost-sharing accumulated: $1,200
• Months remaining (January through December): 12
• January monthly bill: $1,200 / 12 = $100

The beneficiary pays $100 in January. The plan has paid the pharmacy $1,200 and is now waiting to be reimbursed by the beneficiary over the next 12 months.

In February, the beneficiary fills another $500 prescription.

• Total cost-sharing accumulated: $1,200 + $500 = $1,700
• Amount already paid to plan in January: $100
• Remaining M3P balance: $1,700 - $100 = $1,600
• Months remaining (February through December): 11
• February monthly bill: $1,600 / 11 = $145.45

The beneficiary's monthly bill increased because of the new February fill. But the bill is still manageable compared to paying $500 at the counter in February.

In March, suppose no new fills occur.

• Accumulated cost-sharing: $1,700 (unchanged)
• Amount paid to plan through February: $100 + $145.45 = $245.45
• Remaining M3P balance: $1,700 - $245.45 = $1,454.55
• Months remaining (March through December): 10
• March monthly bill: $1,454.55 / 10 = $145.45

The monthly bill remains $145.45 when no new fills occur. The beneficiary pays $145.45 each month through December, by which point the full $1,700 is paid.

If the beneficiary fills another prescription mid-year, the calculation continues to recalibrate. The result is a manageable monthly payment that reflects the beneficiary's cumulative cost-sharing spread over the year.

The out-of-pocket cap interaction

The Medicare Part D out-of-pocket cap, established by Section 11201 IRA 2022, is the safety net that limits the maximum annual obligation under M3P. The cap limits total annual cost-sharing at $2,100 in 2026 (up from $2,000 in 2025, indexed annually for inflation).

The cap interacts with M3P in two ways. First, the cap limits the total amount the plan can bill the beneficiary under M3P. Even if a beneficiary's cumulative cost-sharing at standard rates would exceed $2,100, only the first $2,100 is billable. The plan pays the rest entirely.

Second, the cap ensures that beneficiaries reach $0 cost-sharing relatively early in the year if they have high prescription costs. A beneficiary with a $4,000 specialty drug might hit the $2,100 cap in January. After January, all additional fills are $0 at the counter (and $0 added to M3P balance). The M3P balance is fixed at $2,100, spread over the remaining 11 months.

The combined effect of M3P and the $2,100 cap is unprecedented protection for beneficiaries on high-cost drugs. Without these protections, a beneficiary on a $4,000 monthly biologic might face $48,000 in annual cost-sharing (in the pre-IRA world of unlimited Part D OOP). With the cap, the maximum is $2,100. With M3P, even that $2,100 is spread across 12 months ($175/month).

The Drug Price Negotiation Program interaction

The Medicare Drug Price Negotiation Program, established by Section 11401 IRA 2022, takes effect for the first 10 selected drugs on January 1, 2026. The 10 drugs include Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and Fiasp.

M3P is available for negotiated drugs. The interaction between negotiated drugs and M3P is particularly important for the highest-cost negotiated drugs (Enbrel, Imbruvica, Stelara). A single fill of these drugs can immediately hit the $2,100 OOP cap.

Consider a beneficiary prescribed Stelara in January 2026. The beneficiary's cost-sharing on Stelara (under standard Part D rules) would push them quickly to the $2,100 OOP cap. Without M3P, the beneficiary would pay up to $2,100 at the January fill, then $0 for the rest of the year. With M3P, the $2,100 is spread across 12 months at $175/month, dramatically smoothing the cash flow.

The combined effect of negotiated drug pricing + $2,000 cap + M3P is the most consumer-friendly Part D environment in the program's history. Beneficiaries on high-cost specialty drugs see substantially lower prices, capped annual obligations, and the option to spread payments across the year.

The insulin $35 cap interaction

The Medicare insulin $35 cap, established by Section 11406 IRA 2022, caps insulin cost-sharing at $35 per 30-day supply per insulin product.

M3P is available on insulin. Most beneficiaries on insulin will find that their annual insulin cost-sharing ($35 × 12 = $420) is manageable as a counter payment. M3P is generally not needed for insulin alone. However, beneficiaries on insulin plus other high-cost drugs may opt into M3P for the combined smoothing benefit.

The insulin $35 cap also includes the deductible waiver. Insulin is not subject to the Part D deductible. The M3P calculation includes only the actual cost-sharing ($35/month), not any deductible amount.

The Low-Income Subsidy interaction

The Part D Low-Income Subsidy (LIS, "Extra Help"), expanded by Section 11404 IRA 2022, provides $0 premium, $0 deductible, and low copays (up to $12.65 per drug in 2026) for beneficiaries with income up to 150 percent FPL. LIS recipients pay so little cost-sharing that M3P is generally unnecessary.

However, LIS recipients may opt into M3P if they prefer the predictable monthly billing or if they have many prescriptions and the cumulative cost-sharing creates cash flow issues. The choice is voluntary; LIS does not preclude M3P.

For most LIS recipients, the recommendation is to skip M3P. The annual LIS cost-sharing on typical medication regimens is $200 to $500, paid as small amounts at each fill. Adding M3P billing complexity for a $200 annual obligation provides little benefit.

For LIS recipients on multiple specialty drugs, M3P may be useful. The LIS reduces cost-sharing on each drug to low fixed amounts, but with multiple drugs, the cumulative monthly cost-sharing can still be significant.

The vaccines $0 cost-sharing interaction

ACIP-recommended vaccines (Shingrix, RSV, Tdap, MMR adult catch-up, hepatitis A, meningococcal, and others) are $0 cost-sharing under Section 11401 IRA 2022 for Part D-covered vaccines, and Part B-covered vaccines (flu, pneumococcal, COVID-19, hepatitis B high-risk) are $0 under the ACA 2010.

Because vaccines are $0, M3P is irrelevant for vaccine cost-sharing. No accumulation toward the M3P balance occurs from vaccines. Beneficiaries can receive ACIP-recommended vaccines without any M3P consideration.

When should you opt into M3P

The decision to opt into M3P depends on the beneficiary's prescription profile, cash flow, and financial preferences. Several factors favor opting in:

• High upfront prescription costs (specialty drugs over $500 per fill)
• Annual OOP expected to approach or hit the $2,100 cap
• Limited monthly cash flow (Social Security income with modest cushion)
• Difficulty paying $1,000+ at the pharmacy counter in a single month
• Multiple drugs with combined high cost-sharing
• Chronic conditions requiring biologics (cancer, MS, RA, hepatitis C)
• Preference for predictable monthly billing

Several factors favor opting out:

• Cost-sharing already low (only generics, $4.50 copay)
• LIS recipient with low copays
• Adequate liquidity to pay at the counter without strain
• Preference for simplicity (pay at counter, no monthly bill)
• Concern about managing additional monthly bill alongside other expenses

For Georgia beneficiaries facing the choice, free counseling through GeorgiaCares (1-866-552-4464) is available. SHIP counselors can review the beneficiary's specific situation and help decide.

How to opt into M3P

Opting into M3P is a simple process. The beneficiary contacts their Part D plan and requests M3P enrollment. Most plans offer multiple opt-in channels:

• Online through the plan's member portal
• By phone to the plan's customer service line
• By paper form mailed to the plan
• In person at the plan's local office (if applicable)

The plan must process the opt-in request within 24 hours under CMS rules. Once processed, M3P is effective for the next prescription fill (or the date of opt-in for retrospective fills, depending on the plan's procedures).

The opt-in is for the remainder of the plan year. The beneficiary may opt out at any time, but opt-out applies to future fills only; the accumulated M3P balance must still be paid over remaining months.

How to opt out of M3P

Opting out is also straightforward. The beneficiary contacts the Part D plan and requests M3P termination. The plan must process the opt-out promptly.

Important considerations when opting out:

• The accumulated M3P balance continues to be billed in monthly installments
• Future fills (after opt-out) are paid at the pharmacy counter at standard cost-sharing
• The beneficiary cannot retroactively "un-do" prior M3P fills

If a beneficiary's financial situation changes during the year (inheritance, return to work, decrease in expenses), they may opt out without penalty. The remaining M3P balance is paid over the remaining months at the same rate.

Worked example 1: Margaret 72 Atlanta cancer drug M3P

Margaret is a 72-year-old retiree living in Atlanta. She is enrolled in a Humana Medicare Advantage prescription drug plan (MA-PD). In February 2026, Margaret is diagnosed with breast cancer. Her oncologist prescribes Ibrance (palbociclib), an oral chemotherapy biologic with a retail price of approximately $13,000 per month.

Margaret's Part D cost-sharing on Ibrance under her plan: 33 percent coinsurance up to the $2,100 OOP cap. The first fill in February: 33 percent of $13,000 = $4,290, capped at $2,100. She hits the $2,100 OOP cap in February.

Without M3P, Margaret would pay $2,100 at the February fill, and $0 for all subsequent Ibrance fills through December. The $2,100 February payment is impossible for Margaret to manage in a single month.

Margaret opts into M3P at the time of her diagnosis. The plan pays the pharmacy the $2,100 cost-sharing at the February fill. Margaret pays $0 at the counter. Her M3P balance is $2,100.

Monthly billing calculation:

• February: $2,100 / 11 (months Feb-Dec) = $190.91
• Subsequent months: $190.91 (since no further cost-sharing accumulates after hitting the cap)

Margaret pays $190.91 per month from February through December. Total: $2,100. The cash flow benefit is decisive: she can manage $190.91/month from her Social Security and pension, but could not have managed $2,100 in a single month.

Worked example 2: Robert 68 Savannah multiple drugs M3P decision

Robert is a 68-year-old retiree living in Savannah. He is enrolled in a UnitedHealthcare Part D standalone PDP. Robert takes 5 brand-name drugs and 3 generic drugs for various chronic conditions (type 2 diabetes, hypertension, hyperlipidemia, COPD, depression). His monthly cost-sharing is approximately $300.

Annual cost-sharing: approximately $3,600 retail, capped at $2,000 under Section 11201 IRA. Robert would hit the cap in approximately July.

Robert considers M3P. He calculates:

• Without M3P: pays $300/month from January through July, then $0 from August through December
• With M3P: pays approximately $167/month all year (the $2,000 cap spread over 12 months)

Robert decides to opt out of M3P. He prefers paying at the counter for simplicity. The $300/month is manageable on his Social Security and modest savings. The summer relief (when he hits the cap and pays $0) is welcome.

Robert's case illustrates that M3P is not always the best choice. For beneficiaries with manageable monthly OOP and adequate liquidity, paying at the counter avoids the billing complexity and provides natural relief once the cap is hit.

Worked example 3: Linda 70 Macon Stelara M3P 2026

Linda is a 70-year-old retiree living in Macon. She is enrolled in an Aetna MA-PD plan. Linda has severe rheumatoid arthritis (RA) and has been prescribed Stelara (ustekinumab) for her condition. Stelara is one of the first 10 negotiated drugs under Section 11401 IRA 2022, with a Maximum Fair Price of $4,695 per fill effective January 2026 (down from approximately $13,836 pre-negotiation).

Linda's cost-sharing on Stelara under her plan: 25 percent coinsurance up to the $2,000 OOP cap. The January fill: 25 percent of $4,695 = $1,174 in cost-sharing. The February fill: $1,174 cost-sharing, but her cumulative cost-sharing now exceeds $2,000. She hits the cap in February.

Linda opts into M3P at the January fill. Her plan pays the $1,174 January cost-sharing to the pharmacy. M3P balance: $1,174.

January monthly bill: $1,174 / 12 = $97.83

In February, Linda fills Stelara again. The 25 percent coinsurance would be $1,174, but she hits the $2,000 cap. She owes only $826 to reach the cap. After February, no further cost-sharing accumulates.

• M3P balance after February: $2,000 (capped)
• February bill: $2,000 already accumulated, with $97.83 already paid in January. Remaining $1,902.17, divided over 11 months = $172.93
• March through December bills: $172.93 each (assuming no further fills add to balance, which is true because cap is hit)

Linda pays $97.83 in January, then $172.93 per month from February through December. Total: $97.83 + ($172.93 × 11) = $97.83 + $1,902.23 = $2,000.06 (rounding). She has Stelara coverage for the full year and her monthly cost is manageable.

Worked example 4: Charles 73 Augusta retroactive M3P opt-in

Charles is a 73-year-old retiree living in Augusta. He is enrolled in an Anthem Part D PDP. In January 2026, Charles fills several prescriptions at the pharmacy without using M3P. His January cost-sharing totals $400, which he paid at the counter.

In February, Charles learns about M3P from a GeorgiaCares counselor. He opts in. The opt-in is effective for future fills (February forward), not retroactive to January.

February fill cost-sharing: $300. Charles pays $0 at the counter; the plan pays the pharmacy. M3P balance: $300.

Monthly billing calculation:

• January: $400 paid at counter (not in M3P balance)
• February M3P balance: $300, divided over 11 remaining months = $27.27
• Subsequent fills: added to M3P balance as they occur

Charles's case illustrates that M3P is not retroactive to fills paid at the counter. Beneficiaries who want M3P benefit should opt in early in the plan year (or before high-cost fills). Mid-year opt-in is permitted but only applies to future fills.

Worked example 5: Patricia 65 Columbus insulin M3P

Patricia is a 65-year-old new Medicare beneficiary living in Columbus. She has type 2 diabetes and uses Lantus (insulin glargine). Lantus is covered under Section 11406 IRA 2022 with the $35 monthly cap.

Patricia's annual insulin cost-sharing: $35 × 12 = $420. This is manageable as a counter payment.

Patricia opts into M3P primarily for predictable monthly billing. Her M3P monthly bill: $420 / 12 = $35 per month. This is essentially the same as paying $35 at the counter each month.

Patricia's case illustrates that M3P can be used for budget smoothing even when not strictly needed. The mechanism provides predictability and consolidates the beneficiary's drug cost-sharing into a single monthly bill from the plan.

Worked example 6: Henry 75 Athens M3P opt-out mid-year

Henry is a 75-year-old retiree living in Athens. He is enrolled in a WellCare Part D PDP. Henry opts into M3P in January 2026. He has multiple chronic conditions and high cost-sharing.

By July 2026, Henry has accumulated $1,800 in M3P balance. He has paid $1,050 ($150/month × 7 months) through July.

In July, Henry receives an inheritance of $25,000. His financial situation improves. He no longer needs M3P for cash flow smoothing.

Henry contacts WellCare and opts out of M3P. WellCare processes the opt-out. Future fills (August forward) are paid at the pharmacy counter.

The accumulated M3P balance ($1,800 - $1,050 = $750 remaining) continues to be billed. Over the 5 remaining months (August-December), Henry pays $150 per month.

In August, Henry fills additional prescriptions at the counter at standard cost-sharing. He pays at the pharmacy. These do not add to the M3P balance.

If Henry's cumulative cost-sharing reaches $2,000 (he had $1,800 in M3P balance + $200 in subsequent counter fills), he hits the cap. All further fills are $0.

Henry's case illustrates that M3P is voluntary and reversible. Beneficiaries can opt out without penalty if their situation changes. The accumulated balance is paid down over remaining months, but new fills can be handled at the counter at standard cost-sharing.

Common mistakes Georgia beneficiaries make

Many Georgia Medicare beneficiaries make avoidable mistakes when considering M3P. Understanding the rules helps avoid these mistakes.

The first mistake is thinking M3P reduces total cost. It does not. M3P only spreads cost over time. Total cost is the same; the timing changes. Beneficiaries hoping for a discount are disappointed.

The second mistake is believing M3P is automatic. It is not. Beneficiaries must affirmatively opt in. Plans must inform members about M3P, but members must take action to enroll.

The third mistake is confusing M3P with manufacturer copay coupons or charitable assistance grants (PAN Foundation, HealthWell Foundation). These are separate programs that may reduce cost-sharing; M3P is a payment plan that spreads cost-sharing.

The fourth mistake is not realizing M3P is plan-specific. The M3P balance belongs to the specific Part D plan. If the beneficiary changes plans at year-end, the M3P balance must be settled with the old plan. The new plan does not inherit the balance.

The fifth mistake is thinking LIS recipients should always opt in. LIS already provides low cost-sharing. M3P adds billing complexity for little benefit. Most LIS recipients should skip M3P.

The sixth mistake is missing the $2,000 OOP cap interaction. The cap protects total annual cost. M3P + cap = capped annual obligation spread over the year. The combination is unprecedented protection.

The seventh mistake is not understanding mid-year opt-in. M3P is not retroactive. Beneficiaries who want M3P should opt in before high-cost fills.

The eighth mistake is thinking M3P imposes interest or fees. It does not. The monthly amount equals the cost-sharing without markup.

The ninth mistake is not opting out when the situation changes. Beneficiaries can opt out at any time. If finances improve, opting out simplifies billing.

The tenth mistake is failing to use free counseling. GeorgiaCares (1-866-552-4464) provides free unbiased advice on whether M3P is right for the beneficiary's specific situation.

How M3P fits into the broader IRA 2022 reform package

M3P is one of five major Part D consumer protections in the IRA 2022:

1. Drug Price Negotiation Program (Section 11401): negotiated prices on selected high-cost drugs
2. $2,000 Out-of-Pocket Cap (Section 11201): annual cost-sharing cap
3. Medicare Prescription Payment Plan (Section 11202): monthly smoothing of OOP costs
4. Insulin $35 Cap (Section 11406): insulin cost-sharing cap
5. ACIP Vaccines $0 Cost-Sharing (Section 11401): vaccine cost elimination

The Part D Low-Income Subsidy expansion (Section 11404) is the sixth IRA Part D reform, which eliminated the Partial LIS tier and expanded Full LIS coverage.

Together, these reforms represent the most significant consumer-friendly changes to Medicare Part D since the program's creation in 2003. For Georgia beneficiaries on high-cost drug regimens, the combined effect is substantial savings, capped annual obligations, and the option to spread payments across the year.

The reforms are also interconnected. Negotiated drugs are subject to the $2,000 cap. M3P applies to negotiated drugs. Insulin is capped at $35 but can also use M3P. Vaccines are $0 and outside both caps. LIS recipients benefit from low copays before any cap or smoothing kicks in. The framework is designed to provide multiple, complementary protections.

How Brevy supports Georgia Medicare beneficiaries

Brevy (brevy.com) provides comprehensive Medicare and Medicaid resources for Georgia families. Our state-by-state guides cover the Medicare Prescription Payment Plan, $2,000 OOP cap, negotiated drugs, insulin cap, vaccines, LIS, and many other topics. We update our content as federal and state rules evolve. Our goal is to be the most trustworthy and up-to-date eldercare resource for American families. For free unbiased counseling on a specific case, contact GeorgiaCares (SHIP) at 1-866-552-4464.

::: accordion Frequently asked questions about Georgia Medicare Prescription Payment Plan

What is the Medicare Prescription Payment Plan?

The Medicare Prescription Payment Plan (M3P) is a payment option for Medicare Part D beneficiaries that allows them to spread their out-of-pocket prescription drug costs across the plan year in monthly installments. M3P was established by Section 11202 of the Inflation Reduction Act of 2022 and codified at Section 1860D-2(b)(2)(E) of the Social Security Act.

When did M3P take effect?

M3P took effect January 1, 2025, after a phased implementation announced in CMS rulemaking. The 2024 final rule (89 Fed. Reg. 71684, September 6, 2024) established the operational requirements.

Is M3P automatic or do I have to enroll?

M3P is voluntary. Beneficiaries must affirmatively opt in. Plans must offer M3P and inform members, but members must take action to enroll.

How do I enroll in M3P?

Contact your Part D plan and request M3P enrollment. Most plans offer multiple opt-in channels: online through the member portal, by phone to customer service, by paper form, or in person at the plan's local office. Plans must process opt-in requests within 24 hours.

How does M3P calculate my monthly bill?

The basic formula is: Accumulated cost-sharing divided by remaining months in the plan year. Each month, as new fills are added to the balance, the monthly bill recalibrates. The $2,000 OOP cap (Section 11201 IRA 2022) limits the total annual obligation.

Does M3P reduce my total cost?

No. M3P only spreads cost over time. The total cost is the same as paying at the pharmacy counter. The benefit is timing, not amount.

Is M3P available on all Part D plans?

Yes. All Part D plans (standalone PDPs and Medicare Advantage prescription drug plans, MA-PDs) must offer M3P under federal law.

Are there interest charges or fees for M3P?

No. The monthly amount equals the cost-sharing without markup. Plans cannot impose interest or fees beyond the actual cost-sharing.

Can I opt out of M3P during the year?

Yes. You can opt out at any time. The accumulated balance continues to be billed in monthly installments. Future fills (after opt-out) are paid at the pharmacy counter at standard cost-sharing.

Can I opt in mid-year?

Yes. Mid-year opt-in is permitted, but only applies to future fills. Prior fills paid at the counter are not retroactively added to the M3P balance.

How does M3P interact with the $2,000 OOP cap?

The $2,000 cap limits the total annual obligation. M3P spreads the obligation across the year. Once the cap is reached, no further cost-sharing accumulates and future fills are $0. The capped $2,000 is spread over the remaining months at the M3P rate.

How does M3P interact with negotiated drugs?

M3P is available on negotiated drugs. The Drug Price Negotiation Program (Section 11401 IRA 2022) lowers the price of selected drugs effective January 2026. Even at the lower negotiated prices, the cost-sharing on high-cost negotiated drugs (Enbrel, Imbruvica, Stelara) can hit the $2,000 cap. M3P spreads the capped $2,000 across the year.

How does M3P interact with the insulin $35 cap?

The insulin $35 cap (Section 11406 IRA 2022) limits insulin cost-sharing to $35 per 30-day supply. M3P is available on insulin. For most beneficiaries, $35/month is manageable at the counter; M3P may not be necessary. But beneficiaries on insulin plus other high-cost drugs may use M3P for combined smoothing.

How does M3P interact with the Low-Income Subsidy?

LIS recipients have low cost-sharing ($4.50 generic / $11.20 brand in 2026). M3P is generally not needed for LIS recipients. The annual LIS cost-sharing is typically small enough to manage at the counter. LIS recipients may still opt in if they prefer.

Are vaccines included in M3P?

ACIP-recommended vaccines are $0 cost-sharing under Section 11401 IRA 2022. Vaccines do not add to the M3P balance. M3P is irrelevant for vaccine cost-sharing.

What happens if I change Part D plans during open enrollment?

The M3P balance is plan-specific. If you change plans at year-end, the M3P balance must be settled with the old plan. The new plan does not inherit the balance. Plan to factor M3P obligations into your plan-change decision.

What happens if I miss an M3P payment?

The plan may impose late fees or pursue collection under consumer protection rules. However, the plan cannot deny prescriptions for missed M3P payments. Medication adherence is protected.

Who benefits most from M3P?

Beneficiaries with high upfront prescription costs, multiple drugs, limited monthly cash flow, chronic conditions requiring biologics (cancer, MS, RA), or annual OOP that hits the $2,000 cap in a single month. M3P transforms high counter payments into manageable monthly installments.

Who benefits less from M3P?

LIS recipients, beneficiaries on only generic medications with low cost-sharing, beneficiaries with annual OOP under $500 to $1,000, and beneficiaries who prefer simplicity (paying at the counter).

How many beneficiaries are enrolled in M3P?

Approximately 1.4 million Medicare beneficiaries opted into M3P in 2025 (the first year). Approximately 28,000 of those were Georgia residents. Uptake is expected to grow as awareness increases.

Is M3P available on Medicare Advantage prescription drug plans?

Yes. Both standalone Part D plans (PDPs) and Medicare Advantage prescription drug plans (MA-PDs) must offer M3P.

Can I use M3P with charitable assistance programs?

Yes. M3P and charitable assistance programs (like Patient Access Network Foundation or HealthWell Foundation) operate independently. Charitable grants may reduce the cost-sharing amount before it is added to the M3P balance.

What happens at the end of the plan year if I have a remaining M3P balance?

The remaining balance is due by the end of the plan year (or per the plan's terms). Some plans may allow extended payment beyond the plan year; others may not. Check with your specific plan.

Where can I get free help deciding whether to use M3P?

GeorgiaCares (SHIP) at 1-866-552-4464 provides free unbiased counseling. Medicare Rights Center (1-800-333-4114) and Center for Medicare Advocacy (1-860-456-7790) also provide guidance.

Is M3P different from a prescription assistance program?

Yes. M3P is a payment plan that spreads cost-sharing over time. Prescription assistance programs (manufacturer copay coupons, PAN Foundation, HealthWell Foundation) may reduce the cost-sharing amount. The two are independent and can be used together. :::

::: cta Get help with the Medicare Prescription Payment Plan in Georgia

• DCH Medicaid Member Services 1-866-211-0950
• Medicare 1-800-MEDICARE (1-800-633-4227)
• GeorgiaCares (SHIP) 1-866-552-4464
• Social Security Administration 1-800-772-1213
• Medicare Rights Center 1-800-333-4114
• Center for Medicare Advocacy 1-860-456-7790
• Justice in Aging 202-289-6976
• Atlanta Legal Aid Senior Citizens Law Project 404-377-0701
• Georgia Legal Services Program 1-800-498-9469
• 211 Georgia
• Eldercare Locator 1-800-677-1116
• AARP Georgia 1-866-295-7283
• Patient Access Network Foundation 1-866-316-7263
• HealthWell Foundation 1-800-675-8416
• Maximus Federal Services (Medicare IRE) 1-833-919-0198
• CMS Region IV Office (Atlanta): contact through 1-800-MEDICARE
• Medicare Beneficiary Ombudsman: contact through 1-800-MEDICARE
• BenefitsCheckUp (National Council on Aging) at benefitscheckup.org :::

This guide is provided by Brevy (brevy.com) as a public education resource. It does not constitute legal, medical, or financial advice. Medicare rules and Part D plan terms change frequently. M3P operational details vary by plan. For specific guidance on your situation, consult the agencies and organizations listed above, including GeorgiaCares (1-866-552-4464) for free unbiased counseling, or speak with a licensed Medicare agent. Last verified May 13, 2026.